Mikkelsen Nanna S, Hernandez Sabina S, Jensen Trine I, Schneller Jessica L, Bak Rasmus O
Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
RNA and Gene Therapies, Novo Nordisk A/S, Maaloev, Denmark.
Mol Ther Methods Clin Dev. 2023 Feb 16;29:1-16. doi: 10.1016/j.omtm.2023.02.010. eCollection 2023 Jun 8.
CRISPR-Cas-mediated site-specific integration of transgenes by homology-directed repair (HDR) is challenging, especially in primary cells, where inferior editing efficiency may impede the development of gene- and cellular therapies. Various strategies for enrichment of cells with transgene integrations have been developed, but most strategies either generate unwanted genomic scars or rely on permanent integration and expression of a reporter gene used for selection. However, stable expression of a reporter gene may perturb cell homeostasis and function. Here we develop a broadly applicable and versatile enrichment strategy by harnessing the capability of CRISPR activation (CRISPRa) to transiently induce expression of a therapeutically relevant reporter gene used for immunomagnetic enrichment. This strategy is readily adaptable to primary human T cells and CD34+ hematopoietic stem and progenitor cells (HSPCs), where enrichment of 1.8- to 3.3-fold and 3.2- to 3.6-fold was achieved, respectively. Furthermore, chimeric antigen receptor (CAR) T cells were enriched 2.5-fold and demonstrated improved cytotoxicity over non-enriched CAR T cells. Analysis of HDR integrations showed a proportion of cells harboring deletions of the transgene cassette arising either from impartial HDR or truncated adeno-associated virus (AAV) vector genomes. Nonetheless, this novel enrichment strategy expands the possibility to enrich for transgene integrations in research settings and in gene and cellular therapies.
通过同源定向修复(HDR)实现的CRISPR-Cas介导的转基因位点特异性整合具有挑战性,尤其是在原代细胞中,较低的编辑效率可能会阻碍基因和细胞疗法的发展。已经开发了多种用于富集转基因整合细胞的策略,但大多数策略要么会产生不需要的基因组疤痕,要么依赖于用于选择的报告基因的永久整合和表达。然而,报告基因的稳定表达可能会扰乱细胞稳态和功能。在这里,我们利用CRISPR激活(CRISPRa)瞬时诱导用于免疫磁珠富集的治疗相关报告基因表达的能力,开发了一种广泛适用且通用的富集策略。该策略很容易适用于原代人T细胞和CD34+造血干细胞及祖细胞(HSPCs),分别实现了1.8至3.3倍和3.2至3.6倍的富集。此外,嵌合抗原受体(CAR)T细胞富集了2.5倍,并且与未富集的CAR T细胞相比,细胞毒性有所提高。对HDR整合的分析表明,一部分细胞由于不精确的HDR或截短的腺相关病毒(AAV)载体基因组而发生转基因盒缺失。尽管如此,这种新的富集策略扩展了在研究环境以及基因和细胞疗法中富集转基因整合的可能性。